Overview Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta Status: Completed Trial end date: 2007-05-01 Target enrollment: Participant gender: Summary This is an extension study to examine the long-term safety and efficacy of zoledronic acid in patients who have completed the core CZOL446H2202 study. Phase: Phase 2 Details Lead Sponsor: Novartis PharmaceuticalsTreatments: DiphosphonatesZoledronic Acid